# TB-500 Tissue Repair: Wound, Cardiac, and Anti-Fibrotic Research | TB-500 > TB-500 tissue repair research logged to source: rat wound re-epithelialization, cardiac repair, anti-fibrotic findings, and the 2021–2026 delivery-system studies — all on full-length thymosin beta-4. The tissue-repair lens is where the thymosin beta-4 record is richest — and where the fragment-versus-protein caveat matters most. Each finding logged with its species and source. ## TB-500 tissue repair: what the wound record shows TB-500 tissue repair claims trace back to one of the best-characterized findings in the thymosin beta-4 literature: accelerated wound healing in a rat full-thickness model. Topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, raised wound contraction by at least 11% by day seven, and increased collagen deposition and angiogenesis; in migration assays, as little as 10 pg stimulated keratinocyte movement two- to three-fold [3]. Those are precise numbers, and they are the reason "tissue repair" is the dominant frame for this molecule. They are also rat data on the full-length protein — the standing caveat applies. Thymosin beta-4 also promoted matrix metalloproteinase expression during wound repair, supporting the extracellular-matrix remodeling that healing requires [7]. The mechanism a 2012 review consolidated — migration, anti-scarring, anti-inflammatory, angiogenic — is exactly the mechanism a wound needs [5]. The TB-500 fragment carries the actin-binding motif at the center of that program [1]. What the record does not contain is a controlled human trial showing the isolated fragment delivering these wound outcomes in people [10]. ## Does TB-500 help wound healing? ### Does TB-500 help wound healing? In animal models, thymosin beta-4 accelerated wound re-epithelialization, contraction, collagen deposition, and angiogenesis [3], and recent delivery systems improved on it: a 2025 thymosin-beta-4-exosome-loaded hemostatic and antibacterial hydrogel improved vascularized wound repair [14]. Human wound-healing data exist for topical full-length thymosin beta-4, not for the TB-500 heptapeptide. The animal wound case is genuinely strong — multiple models, a defined mechanism, and now engineered delivery vehicles. The honest qualifier is the molecule: "thymosin beta-4 helps wound healing in animals" is supported; "the TB-500 fragment heals human wounds" is not on the record [10]. ## What is the latest research on TB-500 / thymosin beta-4? ### What is the latest research on TB-500 / thymosin beta-4? Recent (2021–2026) thymosin beta-4 work centers on engineered delivery and tissue repair: scaffold-released thymosin beta-4 that activated cardiac cells and promoted cardiac repair (2021) [13]; a thymosin-beta-4-exosome hydrogel for vascularized wound repair (2025) [14]; inhaled thymosin beta-4 against bleomycin-induced pulmonary fibrosis (2024) [12]; thymosin beta-4 modulating inflammation in a mouse fatty-liver model (2025) [11]; zebrafish Mauthner-axon regeneration via actin dynamics (2024) [15]; and a 2026 Sports Medicine review of unapproved musculoskeletal peptides [10]. The through-line of the recent literature is delivery. The newest work is less about whether thymosin beta-4 does something in tissue — that is well established in animals — and more about how to deliver it where it is wanted: scaffolds, exosome hydrogels, and inhalation. Every one of these used the full-length protein. ## Cardiac and anti-fibrotic repair The cardiac leg of the tissue-repair record rests on a defined survival pathway. Thymosin beta-4 forms a complex with PINCH and integrin-linked kinase, activating Akt; after coronary artery ligation in mice it upregulated ILK/Akt, enhanced early myocyte survival, and improved cardiac function [2]. A separate rodent study reported cardioprotection with systemic dosing after ischemic injury [9]. The 2021 self-assembling-peptide delivery study extended the approach to engineered local release, activating cardiac cells from a functionalized scaffold [13]. The anti-fibrotic leg is consistent across tissues. Thymosin beta-4 reduces myofibroblast number, lowering scar formation [5], modulates matrix metalloproteinase expression in wound repair [7], suppressed corneal NF-κB [8], and — in the newest work — suppressed pulmonary fibrosis when inhaled [12] and modulated hepatic inflammation in fatty-liver mice [11]. Reducing myofibroblasts and remodeling matrix is the same anti-scarring program seen in the dermal wound work, surfacing in heart, lung, and liver. The disciplined caveats stay attached. Systemic thymosin beta-4 failed to attenuate ischemia-reperfusion injury in pigs, and chronic thymosin beta-4 in mdx mice did not improve cardiac function or fibrosis despite increasing regenerating fibers. Mixed results temper the narrative; the record carries them in plain sight. ## The angiogenic edge — benefit and the tumor caution Angiogenesis is the connective thread through the tissue-repair record, and it is also the one finding that points two ways at once. Thymosin beta-4 drives endothelial cell migration and differentiation, and that new-vessel growth is part of why wounds close faster, hearts recover better, and engineered delivery vehicles work [5][14]. The 2025 thymosin-beta-4-exosome hydrogel was explicitly built around vascularized wound repair — the angiogenic effect was the design target, not a side note [14]. The same property is the record's most-cited safety caution. Thymosin beta-4 is overexpressed in several cancers and is implicated in metastasis and tumor angiogenesis; the pro-migratory, pro-angiogenic activity that aids repair could theoretically support tumor progression. That caution is a flagged signal in the literature, not an established human risk for the TB-500 fragment, which has no controlled human data at all [10]. The tissue-repair story, read honestly, is therefore a benefit and a liability carried by one mechanism. The animal evidence for repair is genuine and reproducible. The human evidence for the fragment is absent — no completed controlled trial of the heptapeptide exists for any tissue-repair indication [10]. And the same biology that makes the repair signal compelling is the biology the safety caution turns on. --- A phosphor-terminal reading of the TB-500 record — the Ac-LKKTETQ fragment logged green where its studies hold, every full-length thymosin beta-4 substitution flagged as a checksum mismatch, and the empty human-trial line left blinking NULL; no clinic behind the screen and nothing here dispensed or sold.